Spots Global Cancer Trial Database for Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC)
Official Title: A Prospective, Multi-Center, Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Early-Stage Hepatocellular Carcinoma (HCC)
Study ID: NCT01078415
Conditions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of the NanoKnife LEDC System for the treatment of early-stage hepatocellular carcinoma (HCC).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
L'institut de cancerologie Gustave Roussy, Villejuif, Ile-de-France, France
Hopital Beaujon, Paris, , France
Universitatsklinikum Magdeburg AoR, Klinik fur Radiologie und Nuklearmedizin, Magdeburg, , Germany
University of Pisa School of Medicine, Pisa, Tuscany, Italy
Istituto Nazionale Tumori - Fondazione Pascale, Naples, , Italy
Barcelona Clinic Liver Cancer Group, Hospital Clinic i Provincial de Barcelona, Barcelona, , Spain
Contact Details
Name: Riccardo Lencioni, MD
Affiliation: University of Pisa School of Medicine
Role: PRINCIPAL_INVESTIGATOR
Name: Jordi Bruix, MD
Affiliation: Barcelona Clinic Liver Cancer (BCLC) Group of the University of Barcelona
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
